New mRNA flu shot enters human testing
NCT ID NCT05426174
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 34 times
Summary
This early-stage trial tested a new mRNA-based flu vaccine in 233 healthy adults aged 18 and older. The goal was to check safety and how well the vaccine triggers an immune response. Participants received either the experimental mRNA vaccine or a standard high-dose flu shot. Results will help decide if larger studies are warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AES - DRS - Optimal Research_Site 8400001
Peoria, Illinois, 61614-4885, United States
-
AES - DRS - Optimal Research_Site 8400002
Melbourne, Florida, 32934-8172, United States
-
AES - DRS - Optimal Research_Site 8400007
Huntsville, Alabama, 35802, United States
-
Central Phoenix Medical Clinic, LLC_Site: 8400010
Phoenix, Arizona, 85020, United States
-
Optimal Research San Diego, LLC_Site: 8400009
San Diego, California, 92108, United States
-
Synexus Clinical Research_Site 8400003
Cincinnati, Ohio, 45236, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA NA vaccine
What this could lead to
If successful, this could lead to a more effective flu vaccine that targets a different part of the virus, potentially offering broader protection.
What could go wrong
This is an early Phase 1 trial with only 233 participants, so safety and immune response are still being tested. The vaccine may not work as hoped or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.